Battles in the pharmaceutical antitrust world have been increasingly heated, and to a great extent rightly so, as people have devoted more attention to this space in the past decades. But as measured against the U.S. antitrust laws, what has changed or will change in the scrutiny of pharmaceutical companies’ conduct? Eric Grannon, a leading defense practitioner, joins Anora Wang and John Roberti to discuss three main areas—reverse payment, product hopping, and class certification—that get the most heat. Listen to this episode to learn what is about to come in the U.S. pharmaceutical antitrust wars.

Eric Grannon, Partner, White & Case LLP

Related Links:

Watson Pharmaceuticals, Inc., et al. (FTC v. Actavis)

Hosted by:

John Roberti, Allen & Overy LLP and Anora Wang, Winston & Strawn LLP